Cargando…

Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation

Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Sun Young, Kishinevsky, Sarah, Mazzulli, Joseph R., Graziotto, John, Mrejeru, Ana, Mosharov, Eugene V., Puspita, Lesly, Valiulahi, Parvin, Sulzer, David, Milner, Teresa A., Taldone, Tony, Krainc, Dimitri, Studer, Lorenz, Shim, Jae-won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063469/
https://www.ncbi.nlm.nih.gov/pubmed/27641647
http://dx.doi.org/10.1016/j.stemcr.2016.08.012
_version_ 1782459984516218880
author Chung, Sun Young
Kishinevsky, Sarah
Mazzulli, Joseph R.
Graziotto, John
Mrejeru, Ana
Mosharov, Eugene V.
Puspita, Lesly
Valiulahi, Parvin
Sulzer, David
Milner, Teresa A.
Taldone, Tony
Krainc, Dimitri
Studer, Lorenz
Shim, Jae-won
author_facet Chung, Sun Young
Kishinevsky, Sarah
Mazzulli, Joseph R.
Graziotto, John
Mrejeru, Ana
Mosharov, Eugene V.
Puspita, Lesly
Valiulahi, Parvin
Sulzer, David
Milner, Teresa A.
Taldone, Tony
Krainc, Dimitri
Studer, Lorenz
Shim, Jae-won
author_sort Chung, Sun Young
collection PubMed
description Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in these monogenic forms could play a more general role in PD. We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell (iPSC)-derived midbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis. We propose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD pathogenesis and identifying therapeutic targets.
format Online
Article
Text
id pubmed-5063469
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-50634692016-10-19 Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation Chung, Sun Young Kishinevsky, Sarah Mazzulli, Joseph R. Graziotto, John Mrejeru, Ana Mosharov, Eugene V. Puspita, Lesly Valiulahi, Parvin Sulzer, David Milner, Teresa A. Taldone, Tony Krainc, Dimitri Studer, Lorenz Shim, Jae-won Stem Cell Reports Article Parkinson's disease (PD) is characterized by the selective loss of dopamine neurons in the substantia nigra; however, the mechanism of neurodegeneration in PD remains unclear. A subset of familial PD is linked to mutations in PARK2 and PINK1, which lead to dysfunctional mitochondria-related proteins Parkin and PINK1, suggesting that pathways implicated in these monogenic forms could play a more general role in PD. We demonstrate that the identification of disease-related phenotypes in PD-patient-specific induced pluripotent stem cell (iPSC)-derived midbrain dopamine (mDA) neurons depends on the type of differentiation protocol utilized. In a floor-plate-based but not a neural-rosette-based directed differentiation strategy, iPSC-derived mDA neurons recapitulate PD phenotypes, including pathogenic protein accumulation, cell-type-specific vulnerability, mitochondrial dysfunction, and abnormal neurotransmitter homeostasis. We propose that these form a pathogenic loop that contributes to disease. Our study illustrates the promise of iPSC technology for examining PD pathogenesis and identifying therapeutic targets. Elsevier 2016-09-15 /pmc/articles/PMC5063469/ /pubmed/27641647 http://dx.doi.org/10.1016/j.stemcr.2016.08.012 Text en © 2016 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Chung, Sun Young
Kishinevsky, Sarah
Mazzulli, Joseph R.
Graziotto, John
Mrejeru, Ana
Mosharov, Eugene V.
Puspita, Lesly
Valiulahi, Parvin
Sulzer, David
Milner, Teresa A.
Taldone, Tony
Krainc, Dimitri
Studer, Lorenz
Shim, Jae-won
Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title_full Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title_fullStr Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title_full_unstemmed Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title_short Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation
title_sort parkin and pink1 patient ipsc-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and α-synuclein accumulation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063469/
https://www.ncbi.nlm.nih.gov/pubmed/27641647
http://dx.doi.org/10.1016/j.stemcr.2016.08.012
work_keys_str_mv AT chungsunyoung parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT kishinevskysarah parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT mazzullijosephr parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT graziottojohn parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT mrejeruana parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT mosharoveugenev parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT puspitalesly parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT valiulahiparvin parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT sulzerdavid parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT milnerteresaa parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT taldonetony parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT kraincdimitri parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT studerlorenz parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation
AT shimjaewon parkinandpink1patientipscderivedmidbraindopamineneuronsexhibitmitochondrialdysfunctionandasynucleinaccumulation